A Phase 1, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients With Advanced Gastrointestinal Stromal Tumor.

Suzanne George,Michael C Heinrich,Neeta Somaiah,Peter Oppelt,Robert McLeod, Satoshi Nishioka,Madan G Kundu,Xiaozhong Qian,Prasanna Kumar,Abderrahmane Laadem,Yvonne Lau,Brittany P Tran, Maura Fallon,Ololade Dosunmu,Julia Shi,Yoichi Naito

Clinical cancer research : an official journal of the American Association for Cancer Research（2023）

引用 0|浏览9

暂无评分

摘要

Targeting GPR20 with DS-6157a was tolerated in patients with advanced GIST with tumor shrinkage demonstrated in KIT/PDGFRA wild type GIST. However, the study did not proceed further due to lower efficacy outcomes than anticipated.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要